{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:03:51Z","timestamp":1754093031964,"version":"3.41.2"},"reference-count":19,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dazukibart is a humanized monoclonal antibody selectively targeting interferon\u2010\u03b2. The pharmacokinetics (PK), safety, tolerability, and immunogenicity of dazukibart were evaluated in 2 double\u2010blind, randomized, placebo\u2010controlled, single\u2010dose, Phase 1 studies in healthy adults in China (Study 1: N\u00a0=\u00a018; dazukibart 900\u00a0mg\u00a0=\u00a015; placebo\u00a0=\u00a03) and Japan (Study 2: N\u00a0=\u00a012; Cohort 1: dazukibart 300\u00a0mg\u00a0=\u00a05, placebo\u00a0=\u00a01; and Cohort 2: dazukibart 900\u00a0mg\u00a0=\u00a05, placebo = 1). PK parameters were assessed after dosing in Study 1 and Study 2, and no significant differences were observed between PK findings among participants in both studies. A biphasic decline in dazukibart serum concentrations was observed in both studies. Exposures increased dose proportionally in Study 2. Body weight, but not race, was identified as an independent covariate of exposure using population PK modeling (including data from a Phase 1 US study [NCT02766621]). No deaths\/discontinuations or serious\/severe adverse events were observed, mostly mild adverse events were reported. No participants in Study 1 were antidrug antibody positive; 20.0% in Study 2 were positive for treatment\u2010induced antidrug antibodies and neutralizing antibodies. PK parameters and immunogenicity rates were consistent with the US study, and no new safety signals were identified.<\/jats:p>","DOI":"10.1002\/cpdd.1522","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T05:44:12Z","timestamp":1747892652000},"page":"572-582","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics, Safety, and Tolerability of Single\u2010Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double\u2010Blind, Phase 1 Studies"],"prefix":"10.1002","volume":"14","author":[{"given":"Naihan","family":"Chen","sequence":"first","affiliation":[{"name":"Development China \u2010 Oncology &amp; Rare Disease Development Clinical Pharmacology, Pfizer Inc  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamato","family":"Sano","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Bioanalytics Pfizer R&amp;D Japan  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine Peking University Third Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuiyi","family":"Hu","sequence":"additional","affiliation":[{"name":"Dev China \u2010 Category 1 Pfizer Inc  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Tabira","sequence":"additional","affiliation":[{"name":"Inflammation &amp; Immunology Clinical Research, Pfizer R&amp;D Japan  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Luo","sequence":"additional","affiliation":[{"name":"China Statistics GBDM, Pfizer Inc  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yoshimatsu","sequence":"additional","affiliation":[{"name":"Biometrics and Data Management Pfizer R&amp;D Japan  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Prybylski","sequence":"additional","affiliation":[{"name":"Pharmacometrics and Systems Pharmacology Pfizer Inc  Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron","family":"Chu","sequence":"additional","affiliation":[{"name":"Immunology and Inflammation Pfizer Inc  Collegeville PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Cardiology and Institute of Vascular Medicine Peking University Third Hospital  Beijing China"},{"name":"Beijing Key Laboratory of Clinical Evaluation of Cardiovascular\u2010Kidney\u2010Metabolic and Immuno\u2010Inflammatory Innovative Drugs and Medical Devices Peking University Third Hospital  Beijing China"},{"name":"Department of Drug Clinical Trials Center Peking University Third Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Takazawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Medical Corporation Shinanokai Shinanozaka Clinic  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2883"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3531"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24936"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2885"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029161"},{"issue":"10","key":"e_1_2_10_7_1","first-page":"410","article-title":"Dermatomyositis and polymyositis: new treatment targets on the horizon","volume":"69","author":"Hak AE","year":"2011","journal-title":"Neth J Med"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2023.2220984"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1309"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14939"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117443"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42526"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15006"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139949"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jvc2.412"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-022-00193-6"},{"issue":"2","key":"e_1_2_10_17_1","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik JJ","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03232-2"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.887"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/11535960-000000000-00000"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T03:50:53Z","timestamp":1754020253000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/cpdd.1522"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1522","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"type":"print","value":"2160-763X"},{"type":"electronic","value":"2160-7648"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"2024-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}